This is an unprecedented time in biomolecular medicine. 1) Recent scientific findings have determined biofluids consist of circulating tumor cells (CTCs), cell-free nucleic acid (cfNA), or extracellular vesicles from multiple tissues within the body. 2) Rapid development of highly sensitive and accurate next-generation sequencing (NGS) technologies has allowed analysis of the role of these biomolecules, and has been rapidly adopted into molecular diagnostic laboratories. And 3) researchers are empowered to analyze the role of these biomolecules in health, disease and treatment response leading to targeted therapies. However, there still remains insecurity associated with biofluid-based DNA/RNA analytical methods, which must be solved before liquid biopsies can be implemented for broader routine applications. At The Liquid Biopsy Summit, experts present and consider process and technology refinements that can enable molecular liquid biopsies to become a fulcrum in the future of precision medicine.
New Tools for Liquid Biopsies: Microfluidic Platforms for the Isolation of CTCs, cfDNA and Exosomes
Steven A. Soper, Ph.D., Foundation Distinguished Professor, Department of Chemistry, Department of Mechanical Engineering; Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas
Epigenetic and Genetic Analysis of Exfoliated Cells for Cancer Prognosis
Tim Hui-Ming Huang, Ph.D., Professor & Chair, Department of Molecular Medicine, University of Texas Health Science Center
Pre-Analytical Variables in Blood Collection Impact on Precision Medicine
Carolyn Compton, M.D., Ph.D., CMO, Complex Adaptive Systems Institute, Arizona State University